Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration (PERSEUS)

Bayer

Status: Completed

Conditions: Wet Age-related Macular Degeneration

Treatments: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Study type: Observational

Funder types: Industry

Identifiers

NCT01914380

16623

EY1313DE (Other Identifier)

Details and patient eligibility

About

The study aims to investigate the effectiveness of Eylea in patients with wet age-related macular degeneration in routine clinical practice in Germany. The study is purely observational, only data from routine treatment are to be collected. The treatment and treatment conditions are solely at discretion of the treating physician.

Enrollment: 988 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with wet wAMD treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC).
• Written informed consent.

Exclusion criteria

• Exclusion criteria as listed in the local SPC.
• Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
• Any concomitant therapy with another agent to treat wet AMD in the study eye.

Trial design

988 participants in 1 patient group

Group 1

Treatment:

Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)